Endpoint 6: Percentage of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 2, 8, 12, 16 and 24 Statistical Analysis

Statistical analysis title	ACR70 Week 2: SBI-087/ Placebo/ Placebo
Comparison groups	SBI-087/ Placebo/ Placebo vs. Placebo/Placebo/Placebo
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.663
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 2: SBI-087/ Placebo/ Placebo
Comparison groups	SBI-087/ SBI-087/ Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.471
Method	Cochran-Mantel-Haenszel

Statistical analysis title	ACR70 Week 2: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.656
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 2: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.203

Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 8: SBI-087/ Placebo/ Placebo
Comparison groups	SBI-087/ Placebo/ Placebo
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.85
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 8: SBI-087/ SBI-087/ Placebo
Comparison groups	SBI-087/ SBI-087/ Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.035
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 8: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.035
Method	Cochran-Mantel-Haenszel

Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.871
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 12: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087

Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.816
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 12: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority

P-value	= 0.381
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 16: SBI-087/ Placebo/ Placebo
Comparison groups	SBI-087/ Placebo/ Placebo
Number of subjects included in analysis	43

Statistical analysis title	ACR70 Week 8: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.147
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 12: SBI-087/ Placebo/ Placebo
Comparison groups	SBI-087/ Placebo/ Placebo
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.399

Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 12: SBI-087/ SBI-087/ Placebo
Comparison groups	SBI-087/ SBI-087/ Placebo
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.855
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 16: SBI-087/ SBI-087/ Placebo
Comparison groups	SBI-087/ SBI-087/ Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.542
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 16: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087

Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.247
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 16: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.509
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 24: SBI-087/ Placebo/ Placebo
Comparison groups	SBI-087/ Placebo/ Placebo

Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.334
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 24: SBI-087/ SBI-087/ Placebo
Comparison groups	SBI-087/ SBI-087/ Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.279
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 24: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.033
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR70 Week 24: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.02
Method	Cochran-Mantel-Haenszel